Screener
4D Molecular Therapeutics FDMT Total Revenue
Total Revenue at other companies
Segments
Other financials
Where this comes from
Reported directly by 4D Molecular Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:13 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211939
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Revenue: | ||
| Collaboration and license revenue | $3,047 | $14 |
| Operating expenses: | ||
| Research and development | 64,980 | 40,699 |
| General and administrative | 11,687 | 12,936 |
| Total operating expenses | 76,667 | 53,635 |
| Loss from operations | (73,620) | (53,621) |
| Other income (expense): |
Item 1. Condensed Financial Statements (Unaudited)
FAQ
- What is 4D Molecular Therapeutics's total revenue?
- 4D Molecular Therapeutics (FDMT) reported total revenue of $3.05M in Q1 2026.
- How has 4D Molecular Therapeutics's total revenue changed year-over-year?
- 4D Molecular Therapeutics's total revenue increased by 21664.3% year-over-year, from $14K to $3.05M.
- What is the long-term trend for 4D Molecular Therapeutics's total revenue?
- Over 4 years (2021 to 2025), 4D Molecular Therapeutics's total revenue has grown at a 47.4% compound annual growth rate (CAGR), from $18.04M to $85.21M.
- What does total revenue mean?
- The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.
Ask your AI about 4D Molecular Therapeutics's total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude